Case report: Circulating tumor DNA technology displays temporal and spatial heterogeneity in Waldenström macroglobulinemia during treatment with BTK inhibitors
Background: Waldenström macroglobulinemia (WM) is a rare subtype of B-cell lymphoma. Rituximab-based combination therapy and Bruton’s tyrosine kinase (BTK) inhibitors have greatly improved the prognosis of WM. Despite the high response rate and good tolerance of BTK inhibitors in treatment of WM, a...
Main Authors: | Jingjing Zhu, Xinyu Zhu, Fengyang Xie, Yi Ding, Huina Lu, Yan Dong, Ping Li, Jianfei Fu, Aibin Liang, Yu Zeng, Bing Xiu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-04-01
|
Series: | Pathology and Oncology Research |
Subjects: | |
Online Access: | https://www.por-journal.com/articles/10.3389/pore.2023.1611070/full |
Similar Items
-
Zanubrutinib in patients with treatment‐naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded‐access study of 50 patients in the United States
by: Jorge J Castillo, et al.
Published: (2023-02-01) -
Should Patients with Waldenström Macroglobulinemia Receive a BTK Inhibitor as Frontline Therapy?
by: Marina Deodato, et al.
Published: (2022-10-01) -
Ibrutinib-Induced Pancreatitis in Patients with Waldenstrom Macroglobulinemia
by: Nurhilal Büyükkurt, et al.
Published: (2023-06-01) -
Severe nephritis as initial sign of Waldenström’s macroglobulinemia
by: Thomas Knoop, et al.
Published: (2019-12-01) -
Rituximab and Fludarabine or Cyclophosphamide Combination Treatment for Older Waldenström Macroglobulinemia Patients
by: Xiaowei Xu, et al.
Published: (2013-12-01)